EUCTR2007-004011-54-ES进行中（未招募）不适用
Ensayo en fase IIa, aleatorizado, doble ciego, controlado con placebo y de comparación intra-individual entre los miembros izquierdo-derecho en 25 pacientes con dermatitis atópica moderada, para investigar la eficacia, irritación local, seguridad, tolerabilidad y farmacocinética de la aplicación tópica dos veces al día con crema ImCOOH al 10% durante 14 días y una aplicación adicional en el día 15. (Phase IIa, randomized, double-blind, placebo-controlled, intra-individual left-right limb comparison trial in 25 patients with moderate atopic dermatitis to investigate the efficacy, local irritation, safety, tolerability and pharmacokinetics of twice daily topical applications with 10% ImCOOH cream for 14 days with an additional morning application on Day 15.)
Valletta Health BV0 个研究点开始时间: 2007年11月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female aged between 18 and 70 years, extremes included.
- •2. Skin type I, II, III, or IV.
- •3. Able to comply with protocol requirements.
- •4. Informed Consent Form (ICF) signed voluntarily before the first trial-related activity.
- •5. Nonsmoking or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection.
- •6. Normal weight as defined by a Quetelet Index (Body Mass Index [BMI]: weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2, extremes included.
- •7. Patients having atopic dermatitis according to the integrated list with criteria for atopic dermatitis.
- •8. Comparative target areas: minimum 0.1% and maximum 2% of the total body surface area per target area with one site at the left limb and one site at the right limb. Both target areas should be located at the arms (armpits [axillas] are also allowed) or both target areas should be located at the hollows of the knee.
- •9. Topical Atopic Dermatitis Severity Index (toADSI) score of at least 5 for both target areas and the severity of the 2 sites does not differ by more than 3 points.
- •10. General medical condition, in the investigator’s opinion, does not interfere with the assessments and the completion of the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Female subject of childbearing potential without use of effective birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period;
- •Note: Estrogen based hormonal contraception may not be reliable when ImCOOH cream is applied, therefore to be eligible for this trial, women of childbearing potential should either:
- •a. use a double barrier method to prevent pregnancy (i.e., using a condom with either diaphragm or cervical cap);
- •b. use hormonal based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
- •c. use an intrauterine device in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
- •d. be only non-heterosexually active, practice heterosexual abstinence, or have a vasectomized partner (confirmed sterile).
- •Women with tubal ligation are required to use 1 non-hormonal contraceptive method.
- •Women who are postmenopausal for at least 2 years, and women with total hysterectomy are considered of non-childbearing potential.
- •2. A positive pregnancy test or breast feeding at screening.
- •3. A positive HIV-1 or -2 test at trial screening.
- •4. Hepatitis B infection (confirmed by hepatitis B surface antigen) or hepatitis C infection (confirmed by hepatitis C virus antibody) at trial screening.
- •5. Having a target area that is hairy in such extent that in the investigator’s opinion it could influence the application.
- •6. Having a target area that is tattooed.
- •7. Unable to take venous blood samples for pharmacokinetics (PK) outside the elbow fold (fossa cubitus) area in case both elbow folds are part of the target areas.
- •8. Patients receiving radiation therapy, systemic therapy with cytostatics or immunosuppressive drugs within 24 weeks before the first application of trial medication.
- •9. Patients receiving phototherapy or systemic therapy for atopic dermatitis within 4 weeks before the first application of trial medication.
- •10. Patients receiving antibiotics or topical therapy for atopic dermatitis within 2 weeks before the first application of trial medication. However, once-daily use of 1% hydrocortisone acetate is allowed on all lesions with the exception of the test sites and emollients are allowed to be used liberally but not on the test sites.
- •11. Patients taking antihistamines within 1 week before the first application of trial medication.
- •12. Patients with any acute skin infection (superinfection or secondary impetiginisation).
- •13. Any condition (including but not limited to alcohol and drug use), which in the opinion of the investigator could compromise the patient safety or compliance with trial procedures.
- •14. Any history or currently active allergy such as but not limited to drug allergy, food allergy or hay fever.
- •15. Previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the trial medication administered in this trial.
- •16. Participation in an investigational drug trial within 30 days prior to the first application of trial medication.
- •17. Donation of blood or plasma in the 60 days preceding the first application of trial medication.
- •18. Patients with the following laboratory abnormalities at screening:
- •serum creatinine > 1.1 x ULN;
- •hemoglobin = 10.9 g/dL;
- •platelet count grade = 125 x 109/L;
- •absolute neutrophil count = 1.3 x 109/L;
- •aspartate aminotransferase (AST) or alan
研究者
相似试验
进行中（未招募）
1 期
Ensayo en fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con docetaxel (Taxotereâ) frente a docetaxel solo como tratamiento de segunda línea del cáncer de mama avanzado (CMA).Cáncer de mama avanzado (CMA)EUCTR2005-003592-20-ESAstraZeneca AB65
进行中（未招募）
1 期
Estudio para determinar la seguridad y eficacia de la inyección de recMAGE-A3 en pacientes con cáncer de vejiga musculo invasivo positivos a MAGE-A3 tras cistectomia.Patients who get a cystectomy due to muscle invasive bladder cancer which is MAGE-A3 positiveMedDRA version: 14.0Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024355-85-ESEAU Research Foundation273
进行中（未招募）
1 期
Ensayo en fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con Arimidexâ?frente a Arimidexâ?solo como tratamiento de segunda línea en pacientes con cáncer de mama avanzado (CMA) hormonosensible (receptores de estrógeno positivos y/o receptores de progesterona positivos).Cáncer de mama avanzado (CMA) hormono sensible (ER+ve y/o PR+ve)EUCTR2005-003591-38-ESAstraZeneca AB64
进行中（未招募）
不适用
Ensayo de fase IIb, aleatorizado, doble ciego, controlado con placebo, para eltratamiento de la enfermedad celíaca activa con AT-1001Enfermedad celiaquia activaMedDRA version: 9.1Level: LLTClassification code 10007864Term: Celiac diseaseEUCTR2008-000415-14-ESAlba Therapeutics150
进行中（未招募）
1 期
Estudio en fase IIa aleatorizado, doble ciego, controlado con placebo para evaluar los efectos de odanacatib (MK-0822) sobre la densidad mineral ósea (DMO) y la seguridad general en el tratamiento de la osteoporosis en mujeres posmenopáusicas previamente tratadas con alendronato A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate - OdanacatibMedDRA version: 9.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalOsteoporosisEUCTR2008-008257-30-ESMerck & Co., Inc.160